Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients
- PMID: 11190037
- PMCID: PMC1298238
Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients
Abstract
Objective: To identify the risk factors of conjunctival malignant melanoma that predict local tumor recurrence, orbital exenteration, distant metastasis, and tumor-related mortality.
Design: The study group consisted of 150 consecutive patients with a diagnosis of conjunctival melanoma. The clinical parameters of the patient, tumor, and treatment were analyzed in a nonrandomized fashion for their relation to 4 main outcome measures using Cox proportional hazards regression models.
Results: The Kaplan-Meier estimate of local tumor recurrence was 26% at 5 years, 51% at 10 years, and 65% at 15 years. The mean number of recurrences per patient was 1 (median, 0). Ninety-eight patients (65%) had no recurrences, 28 patients (19%) had 1, 11 patients (7%) had 2, 5 patients (3%) had 3, and 8 patients (5%) had 4 or more recurrences. According to multivariate analysis, the factors that predicted local tumor recurrence were the location of the melanoma (not touching the limbus) (P = .01) and tumor-margin pathology (lateral margin involved) (P = .02). Multivariate analysis for features predictive of ultimate exenteration included initial visual acuity (20/40 or worse) (P = .0007), melanoma color (red) (P = .01), and melanoma location (not touching the limbus) (P = .02). Tumor metastasis occurred in 16% of patients at 5 years, 26% at 10 years, and 32% at 15 years. Metastasis was initially in the regional lymph nodes in 17 cases, brain in 4, liver in 3, lung in 2, and disseminated in 1 case. Risks for metastases with use of multivariate analysis included tumor-margin pathology (lateral margin involved) (P = .002) and melanoma location (not touching limbus) (P = .04). Tumor-related death occurred in 7% of patients at 5 years and 13% at 8 years. Risk factors for death with use of multivariate analysis included initial symptoms (lump) (P = .004) and pathologic findings (de novo melanoma without primary acquired melanosis) (P = .05). In a series of univariate analyses, the technique of initial surgery was shown to be an important factor in preventing eventual tumor recurrence (P = .07), metastasis (P = .03), and death (P = .006). Patients who were managed with excisional biopsy using the "no-touch technique" plus alcohol corneal epitheliectomy and supplemental cryotherapy fared far better than those treated with excisional biopsy alone. In addition, the surgical technique used before referral to us was critical. Those patients who had an incisional diagnostic biopsy prior to referral were at risk for more than 1 recurrence (P = .04), and those who had excisional biopsy alone without supplemental cryotherapy were at risk for eventual exenteration (P = .0006) and death (P = .04).
Conclusions: Conjunctival malignant melanoma is a potentially deadly tumor. In this study, metastasis was detected in 26% of patients and death occurs in 13% at 10 years. The surgical technique of tumor management was found to be possibly related to tumor metastases and death. Meticulous surgical planning, use of wide microsurgical excisional biopsy with the no-touch technique, and supplemental alcohol corneal epitheliectomy and conjunctival cryotherapy performed by experienced surgeons are advised. Incisional biopsy should be avoided.
Similar articles
-
Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients.Arch Ophthalmol. 2000 Nov;118(11):1497-507. doi: 10.1001/archopht.118.11.1497. Arch Ophthalmol. 2000. PMID: 11074806
-
Conjunctival melanoma in the Netherlands: a nationwide study.Invest Ophthalmol Vis Sci. 2005 Jan;46(1):75-82. doi: 10.1167/iovs.04-0344. Invest Ophthalmol Vis Sci. 2005. PMID: 15623757
-
Conjunctival melanoma: the role of conservative surgery and radiotherapy in regional metastatic disease.Laryngoscope. 2005 May;115(5):817-22. doi: 10.1097/01.MLG.0000157327.10597.86. Laryngoscope. 2005. PMID: 15867646
-
259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.Breast Cancer Res Treat. 2008 Jun;109(3):405-16. doi: 10.1007/s10549-007-9668-7. Epub 2007 Aug 9. Breast Cancer Res Treat. 2008. PMID: 17687650 Review.
-
Sebaceous carcinoma of the eyelids: personal experience with 60 cases.Ophthalmology. 2004 Dec;111(12):2151-7. doi: 10.1016/j.ophtha.2004.07.031. Ophthalmology. 2004. PMID: 15582067 Review.
Cited by
-
Genetic landscape and prognosis of conjunctival melanoma in Chinese patients.Br J Ophthalmol. 2024 Aug 22;108(9):1306-1312. doi: 10.1136/bjo-2023-324306. Br J Ophthalmol. 2024. PMID: 38383070 Free PMC article.
-
Ocular surface tumors.Oman J Ophthalmol. 2009 Jan;2(1):3-14. doi: 10.4103/0974-620X.48415. Oman J Ophthalmol. 2009. PMID: 21234217 Free PMC article.
-
Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin.Invest Ophthalmol Vis Sci. 2021 Apr 1;62(4):3. doi: 10.1167/iovs.62.4.3. Invest Ophthalmol Vis Sci. 2021. PMID: 33798262 Free PMC article.
-
Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.JAMA Ophthalmol. 2018 Nov 1;136(11):1236-1241. doi: 10.1001/jamaophthalmol.2018.3488. JAMA Ophthalmol. 2018. PMID: 30352118 Free PMC article.
-
Proton radiotherapy in advanced malignant melanoma of the conjunctiva.Graefes Arch Clin Exp Ophthalmol. 2019 Jun;257(6):1309-1318. doi: 10.1007/s00417-019-04286-2. Epub 2019 Mar 27. Graefes Arch Clin Exp Ophthalmol. 2019. PMID: 30919076
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical